BioMarin Pharmaceutical Inc

4 de set. de 2026, 20:07 UTC

BioMarin Pharmaceutical Inc shares are higher in Friday's session, despite earlier pullbacks. No specific news was identified to explain the movement.

3 de set. de 2026, 19:46 UTC

BioMarin Pharmaceutical completes a $275 million acquisition, impacting its strategic positioning. Shares are lower during Thursday's session amid broader biotech M&A activity.

2 de set. de 2026, 23:01 UTC

BioMarin Pharmaceutical Inc. shares declined in after-market trading, reversing earlier gains amid broader market concerns tied to U.S.-Iran tensions and rising oil prices.

1 de set. de 2026, 19:46 UTC

BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics today. Despite this, shares are lower amid integration concerns and ongoing clinical evaluations.

31 de ago. de 2026, 21:01 UTC

BioMarin Pharmaceutical shares are lower in after-market trading amid cautious market sentiment influenced by hawkish comments from Fed Chair Kevin Warsh on inflation.

24 de ago. de 2026, 19:26 UTC

BioMarin Pharmaceutical announced its $275 million acquisition of Alesta Therapeutics. Shares are trading lower amid ongoing market volatility and geopolitical tensions.

21 de ago. de 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, despite earlier gains. Broader market volatility linked to rising crude oil prices may be influencing sentiment.

20 de ago. de 2026, 19:16 UTC

BioMarin Pharmaceutical shares are lower despite BMO initiating coverage with an Outperform rating and a price target of $98.

19 de ago. de 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

18 de ago. de 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, reflecting broader market declines amid profit-taking in technology and concerns over rising bond yields.

17 de ago. de 2026, 19:16 UTC

BioMarin shares are lower despite price target increases from Barclays and Piper Sandler, reflecting ongoing downward performance trends in recent sessions.

14 de ago. de 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13 de ago. de 2026, 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12 de ago. de 2026, 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11 de ago. de 2026, 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10 de ago. de 2026, 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7 de ago. de 2026, 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6 de ago. de 2026, 23:02 UTC

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5 de ago. de 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4 de ago. de 2026, 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3 de ago. de 2026, 23:31 UTC

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31 de jul. de 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30 de jul. de 2026, 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29 de jul. de 2026, 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28 de jul. de 2026, 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27 de jul. de 2026, 19:01 UTC

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24 de jul. de 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 de jul. de 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 de jul. de 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 de jul. de 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.